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Abstract The ability of the activation domain of speci¢c pro-
tein factors to regulate transcription is intimately connected to
their ubiquitin-mediated proteolysis. Here, we provide evidence
that ubiquitin-proteasome function is required for a family of
synthetic viral VP16 transcription activators in mammalian
cells. Blocking the degradation of VP16 activators, through
proteasome inhibitors or by disrupting the ubiquitylation func-
tion, severely compromises their transcriptional activity. Over-
expression of SUG-1, a subunit of the proteasome, reduces both
transactivation and degradation of VP16 activators. The inhib-
itory e¡ect of SUG-1 overexpression is enhanced when a single
non-removable ubiquitin moiety is fused to the amino-terminus
of the VP16 activator. The 19S regulatory subunit of the pro-
teasome physically associates with the general transcription fac-
tor TFIIH, indicating the direct involvement of the proteasome
in transcription. These results support a model in which ubiqui-
tin plays an accessory role, in recruiting the 19S regulatory
subunit of the proteasome, for transcriptional activation.
- 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
In eukaryotic cells, ubiquitin (Ub)-mediated proteolysis is a
major pathway responsible for the destruction of short-lived
transcription factors, including those implicated in the control
of cell growth, signal transduction, programmed cell death
and regulation of transcription [1]. The function and fate of
transcription factors, e.g. Myc, p53, NF-UB and E2F1, are
kept under tight regulatory control through a highly respon-
sive and coordinated Ub-mediated proteolytic process within
cells. The common feature of Ub-mediated proteolysis is that
the highly conserved 76 amino acid Ub protein is covalently
attached to the target proteins through a series of enzymes,
namely E1 Ub-activating enzyme (UBA), E2 Ub-conjugating
enzyme (UBC) and E3 Ub-ligase. E1 ¢rst activates Ub and
transfers the activated Ub to E2. From the E2 enzyme, the Ub
is transferred directly to the target protein or indirectly
through an E3 Ub-protein ligase [2]. The polyubiquitylated
protein is then recognized and degraded by the 26S protea-
some, a large complex with multiple proteolytic activities [1,2].
The proteins targeted for destruction by Ub-mediated pro-
teolysis usually contain an element that signals their ubiqui-
tylation. These elements are often portable and are sometimes
referred to as degrons [2]. The degrons have been found to
overlap transcriptional activation domains (TADs) [3,4]. The
extent of Ub-mediated proteasomal degradation has been
shown to correlate with the potency of the TADs [3,5].
Such convergence of the transcriptional activation and the
proteolytic signaling raises the possibility that the Ub-protea-
some pathway could be involved in both transcriptional acti-
vation and protein degradation and these two events are
somehow linked together, at least for some speci¢c transcrip-
tion factors. Recently, it has been reported in the yeast system
that activator ubiquitylation is essential for transcriptional
activation [3]. In addition, the 19S regulatory subunit of the
26S proteasome has been shown to be required for e⁄cient
transcription elongation by RNA polymerase II [6]. A 19S
proteasome subcomplex was also shown to be recruited to
activate the GAL1-10 promoter in yeast [7]. These observa-
tions underscore the potential link between Ub-mediated deg-
radation and transcriptional activation.
In this report, we show that the Ub-mediated proteolytic
process is involved in transcriptional activation mediated by a
family of synthetic transcription activators derived from a
reiterated eight amino acid sequence from the herpes simplex
viral VP16 TAD. We further provide evidence that SUG-1, a
subunit of the proteasome, is recruited for both transcription
activation and the degradation of VP16 activators. The pre-
sented data also demonstrate that the 19S regulatory subunit
of the proteasome is physically associated with the general
transcription factor TFIIH. These observations reveal a crit-
ical role of ubiquitylation and the proteasome in coordinating
protein degradation and transactivation during transcription.
2. Materials and methods
2.1. Plasmid constructs
The pCG-GAL4 expression constructs, encoding synthetic tran-
scription activators containing the GAL4 DNA binding domain
(BD), fused with one to six copies of VP16 VN8 modules or three
copies of mutant VN8 sequence [3], were acquired from William P.
Tansey. The GAL4 reporter construct pG5-Luc, containing ¢ve copies
of the GAL4 binding sequence, was purchased from Promega. Mam-
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malian expression constructs with Ub moieties fused to the N-termi-
nus of GAL4-VP16 were obtained upon cloning the Ub coding DNA
generated by polymerase chain reaction (PCR) of yeast genomic
DNA. The C-terminal glycine residue of the Ub primer sequence
was changed to alanine. Expression vectors of Myc-tagged SUG-1
and SUG-1m, containing a lysine to methionine mutation at residue
196 (K196M), were constructed by routine PCR-based cloning meth-
ods. Bacterial expression constructs for glutathione S-transferase
(GST) and its fusion proteins were constructed using the pGEX-4T-
1 vector (Amersham Pharmacia Biotech). All recombinant DNA con-
structs were veri¢ed by sequencing.
2.2. Antibodies and biochemicals
Anti-HA (12CA5) and anti-Myc (9E10) antibodies and FuGENE 6
transfection reagents were from Roche Molecular Biochemicals.
Monoclonal anti-GAL4 BD and anti-SUG-1 antibodies were pur-
chased from BD Bioscienes. Rabbit polyclonal antibodies against
the proteasome 19S subunit S1 and TFIIH component XPB were
respectively obtained from A⁄nity BioReagents and Santa Cruz Bio-
technology. Proteasome inhibitors MG132 and lactacystin were from
Calbiochem.
2.3. Cell culture, transient transfection, luciferase reporter assay and
Western blotting analysis
Transient transfections were carried out in NHF (OSU2), LFS
(MDAH041) and HeLa cells at 37‡C or the mouse UBA tempera-
ture-sensitive ts85 cell line [8] at 32‡C as described earlier [9^12]. The
cells were maintained in Dulbecco’s modi¢ed Eagle’s medium supple-
mented with 10% fetal bovine serum. About 18^20 h before trans-
fection, cells were plated at a density of 1^3U105 per 35 mm diameter
dish (or 3^10U105 per 100 mm diameter dish for Western analysis).
The transfection was carried out with FuGENE 6 transfection reagent
according to the manufacturer’s recommendation. Approximately 12 h
after transfection, the DNA^FuGENE mix was removed and cells
were treated with proteasome inhibitor MG132 (1 and 5 WM) or its
dimethylsulfoxide (DMSO) vehicle as a control for an additional 12 h
period. The cells were harvested for luciferase assay and Western
analysis. When needed, ts85 cells were plated at 5U106 per 100 mm
dish, transfected for 24 h and the cells were divided into six 35 mm
diameter dishes and transferred in triplicate to a restrictive temper-
ature regime of 37‡C or permissive 32‡C for another 24 h. In some
experiments, transfection periods were extended to 24 or 48 h and
MG132 (10 WM) was added 10 h before harvesting. The results of
relative luciferase units (RLU) of the enzyme activity assay were
standardized against the total cellular protein and normalized to the
values obtained in controls, or in the absence of MG132. All the
transfection and reporter assay experiments were independently per-
formed at least three times each and error bars represent the S.E.M.
of triplicate data points. For Western blotting analysis, cells were
lysed by boiling for 10 min in sample bu¡er (2% sodium dodecyl
sulfate (SDS), 10% glycerol, 10 mM dithiothreitol, 62 mM Tris^
HCl, pH 6.8, 10 Wg/ml pepstatin and 10 Wg/ml leupeptin) and protein
concentration was determined by DC Bio-Rad assay. Western blotting
was performed using appropriate antibodies and as previously de-
scribed [13,14].
2.4. GST pull-down and immunoprecipitation
Whole cell extracts (WCE) were made from HeLa cells by the
published procedures [15,16]. The WCE were dialyzed overnight
against a⁄nity column bu¡er (10 mM Tris^HCl, pH 7.9, 100 mM
NaCl, 1 mM dithiothreitol, 1 mM EDTA, 10% glycerol) containing
1 mM phenylmethylsulfonyl £uoride and concentrated before GST
pull-down, or GST-Ub-like (Ubl) a⁄nity chromatography. GST
pull-down experiments were performed in the a⁄nity column bu¡er
by incubating the HeLa WCE with the GST fusion proteins loaded
on glutathione Sepharose-4B beads at 4‡C for 1 h. The beads were
washed and bound proteins were recovered by boiling in SDS loading
bu¡er and analyzed by Western blotting. For immunoprecipitation of
GST-Ubl a⁄nity-puri¢ed proteins, the HeLa WCE were applied to a
glutathione Sepharose-4B column previously loaded with GST-Ubl
fusion proteins. After washing the column thoroughly, the bound
proteins were eluted with 10 mM glutathione in 50 mM Tris^HCl
(pH 8.0). The pooled eluates were concentrated using a 10 kDa cut-
o¡ Ultrafree-MC unit. The immunoprecipitation was performed in
the a⁄nity column bu¡er using 1 Wg of either anti-XPB or normal
rabbit IgG at 4‡C for 1 h. Protein A/G agarose beads, previously
equilibrated in column bu¡er containing 100 Wg/ml bovine serum
albumin, were added and the samples were incubated for an extra
hour. The beads were washed four times with a⁄nity column bu¡er
and the bound proteins were eluted and analyzed by Western blotting
using indicated antibodies.
3. Results
3.1. Close correlation between activation, degradation and
MG132-mediated transcriptional inhibition
The convergence of the transcriptional activation and the
proteolytic signaling raises the possibility that the Ub-protea-
some pathway could be involved in both transcriptional acti-
vation and protein degradation. We have addressed this pos-
sibility using a series of synthetic transcriptional activators
(Fig. 1A), derived by the reiteration of an eight amino acid
sequence (DFDLDMLG, VN8) from the VP16 TAD. It may
be noted that several lines of experimental observation have
already described the functional features of these transcription
activators. First, the potency of activators to conduct tran-
scription correlates with their degradation. Second, the integ-
rity of the TAD is essential for both their transactivation and
degradation. A phenylalanine to alanine mutation (DADA-
DMLG, mutant VN8) abolishes transcription, reduces a⁄nity
for transcription factor TFIID [17] and TFIIB [5] and also
protects them from degradation [3,5]. Third, the potency of
transcriptional activators correlates with their ubiquitylation
status, the potent ones being more heavily ubiquitylated than
the weaker ones [3]. So, we asked whether impairment of
proteasome function by proteasome inhibitor could a¡ect
transcriptional activation. As shown in Fig. 1, augmented
copies of VN8 modules increase the transcriptional potency
(Fig. 1B,C) but decrease the steady-state levels of the activator
molecules (Fig. 1E). The MG132 treatment causes a signi¢-
cant accumulation of unstable molecules, con¢rming that
the functional proteasome is required for their degradation
(Fig. 1E). More importantly, MG132 decreases the capacity
of these activators to conduct e¡ective transcriptional activa-
tion and severely inhibits the transcription mediated by the
potent activators. MG132 treatment decreases the transcrip-
tion mediated by GAL4-1U, -2U, -3U and -6U VN8 about
2-, 3-, 4- and 10-fold, respectively. It does not a¡ect the
transcription mediated by GAL4-3UM (three copies of mu-
tant VN8), which has a decidedly reduced transcription po-
tency. Thus, there is a close correlation between the relative
inhibition (absence vs. presence of MG132) of transcriptional
activation and the potency of the activators, except for the
one with only the GAL4 DNA BD (Fig. 1B,C). On the other
hand, the MG132 treatment did not signi¢cantly a¡ect the
transcription driven by the pCMV promoter, indicating
that MG132 inhibition of VP16 activator-mediated transcrip-
tion was speci¢c (Fig. 1D). These results demonstrate that
the impairment of proteasome function by MG132 not only
leads to accumulation of these molecules, but also a¡ects
their ability to conduct transcription; and also indicate that
proteasome function is required for e⁄cient transcriptional
activation by these activators. Since the potency of tran-
scriptional activators is known to correlate with their ubiqui-
tylation status [3], it is easy to surmise that the degradation
of ubiquitylated conjugates is linked to transcriptional activa-
tion events of this family of synthetic transcriptional activa-
tors.
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3.2. Ubiquitylation is required for e⁄cient transcriptional
activation mediated by GAL4-VN8 activators
The impact of impairment of Ub-proteasome function on
transcription mediated by GAL4-VN8 activators was further
substantiated in the ts85 cell line (Fig. 2). These cells harbor a
temperature-sensitive mutation in UBA which leads to a de-
fect in protein ubiquitylation and accumulation of cellular
proteins at the restrictive temperature [8]. Under permissive
temperature conditions (32‡C), a consistent reverse correlation
between transcriptional potency and the steady-state level of
Fig. 1. Proteasome inhibitor MG132 inhibits the degradation of synthetic activators with tandem reiteration of VN8 modules, and reduces their
transcriptional activities. A: Schematic presentation of synthetic activators used in this study. Each synthetic activator contains the GAL4
DNA BD fused to 1U, 2U, 3U, or 6U copies of the wild type VN8 sequence or three copies of mutant VN8 sequence (3UM) as previously
described. B: The inhibitory e¡ects of MG132 on transactivation mediated by synthetic activators are closely correlated to their potencies of
transcriptional activation. 1 Wg of pG5-luc and 1 Wg of expression vector for each synthetic activator were cotransfected into HeLa cells. Twelve
hours after transfection, the cells were treated with 5 WM MG132 or its vehicle DMSO for 12 h and the cells collected for luciferase assay. The
transient transfection/reporter assay was performed at least three times. The luciferase results are normalized against total protein and relative
transcriptional activity is calculated and presented in relation to the basal transcriptional activity of GAL4 DNA BD (v). C: The values calcu-
lated from normalized luciferase activity in the presence vs. absence of MG132 are shown to present relative inhibition by MG132 for each syn-
thetic activator. D: 1 Wg of pCMV-luc was transfected into HeLa cells. Twelve hours after transfection, the cells were treated with 1 or 5 WM
MG132 or its vehicle DMSO for 12 h and the cells collected for luciferase assay. E: Steady-state levels of synthetic activators in transfected
cells. HeLa cells were transiently transfected with expression vector for each synthetic activator and the transfected cells were treated either
with 5 WM MG132 or with its vehicle DMSO. Proteins (60 Wg) of each sample from parallel experiments were used for Western analysis with
anti-HA antibodies.
FEBS 27909 19-12-03
Q. Zhu et al./FEBS Letters 556 (2004) 19^25 21
the activators was also observed in ts85 cells. The steady-state
levels of weaker activators, GAL4-v, -1U and -3UM, but not
of stronger activators, GAL4-2U, -3U, -6U, are clearly de-
tectable by Western analysis of the tagged proteins (Fig.
2A,C, 32‡C). GAL4-3UM had a much reduced transcription-
al potency compared to GAL4-3U. Its transcription activity
and steady-state protein level fall between the values for
GAL4-1U and -2U. This unique pattern of transcriptional
activation and protein level changed when cells were incuba-
ted at the restrictive temperature (37‡C). On the one hand, the
temperature shift greatly compromised the transcription activ-
ity mediated by all these activators, but it had little e¡ect on
the transcription mediated through the pCMV promoter (Fig.
2B). For example, incubation at the restrictive temperature
(37‡C) abolished the transcription by GAL4-1U and -3UM
and attenuated the relative transcription activity of GAL4-
2U, -3U and -6U from 180-, 200- and 280- to only 40-fold,
respectively (Fig. 2). Conversely, incubation at the restrictive
temperature (37‡C) signi¢cantly stabilized these otherwise po-
Fig. 2. Disruption of UBA function leads to an increase in steady-
state levels of unstable synthetic activators but abrogates their tran-
scriptional function. A: ts85 cells were transiently cotransfected with
10 Wg of pG5-luc and 10 Wg of expression vector for each synthetic
activator for 24 h at 32‡C. After transfection, cells were divided and
maintained at either 32‡C or 37‡C in fresh medium and harvested
for luciferase assay 24 h thereafter. The luciferase assay data were
¢rst normalized against total protein and the relative transcriptional
activity (fold) calculated and presented in relation to the basal tran-
scriptional activity of GAL4 DNA BD at 32‡C. B: ts85 cells were
transiently transfected with pCMV-luc expression vector for 24 h at
32‡C. After transfection, cells were divided and maintained at either
32‡C or 37‡C in fresh medium and harvested for luciferase assay 24 h
thereafter. C: The changes in the steady-state levels of synthetic ac-
tivators in ts85 cells upon shifting to the restrictive temperature.
The ts85 cells were transiently transfected with 10 Wg of expression
vector for each synthetic activator for 24 h at 32‡C and cells were
divided and maintained at either 32‡C or 37‡C as described for A.
Proteins (100 Wg) of each sample were used for Western blotting.
Fig. 3. Overexpression of SUG-1WT and SUG-1m interferes with
the degradation and the transactivation by GAL4-VP16 activators.
A: 3U105 LFS cells were transfected with 0 or 1 Wg of GAL4-
VP16 expression vector together with increasing amounts (1, 3 or
5 Wg) of expression vector for either Myc-tagged SUG-1WT (lanes
3^5) or SUG-1m (lanes 6^8) for 48 h. Equal amounts of proteins
from transfected cells were immunoblotted with GAL4, Myc or ac-
tin speci¢c antibodies. B: 1U105 LFS cells were cotransfected with
pG5-Luc (0.25 Wg) and expression vector for GAL4-VP16 or Ub-
(G75A,G76A)-VP16 (0.25 Wg) without or with expression vector for
either Myc-tagged SUG-1WT or SUG-1m (1.5 Wg) for 24 h. Lucif-
erase assay was performed as described in Section 2. Representative
results from three independent experiments are shown as meanU
S.D.
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tent but unstable activators (Fig. 2C). These results demon-
strate that a functional ubiquitylation process is critically im-
portant for Ub-mediated proteolysis. Importantly, the results
indicate that a functioning ubiquitylation process is also re-
quired for e⁄cient transcription mediated by these synthetic
transcriptional activators, albeit the requirement is not simply
related to the transcriptional potency.
3.3. Overexpression of SUG-1, a subunit of the 19S proteasome
complex, leads to accumulation of GAL4-VP16 but
attenuates its transcriptional activation
Since proteasome activity is required for degradation of the
GAL4-VP16 activator, we next investigated whether SUG-1
could be involved in this process. SUG-1 is one of the com-
ponents of the 19S regulatory complex of the 26S proteasome
[18^20]. It is known to directly bind to TAD of GAL4, viral
activator VP16 and thyroid hormone and retinoid-X receptor
[21^23]. To investigate whether SUG-1 participates in the deg-
radation of the GAL4-VP16 activator, competition experi-
ments were carried out by transfection of GAL4-VP16 ex-
pressing constructs with increasing amounts of an expression
vector for either SUG-1WT or SUG-1m, which contains a
dominant negative K196M mutation at the AAA ATPase
module [24,25]. Overexpressed SUG-1 abrogates the degrada-
tion of the GAL4-VP16 activator (Fig. 3A, lanes 2^5). A
similar e¡ect was seen with the overexpression of SUG-1m
(Fig. 3A, lanes 2, 6^8). The observed e¡ect of SUG-1m is
clearly speci¢c because the levels of actin control were unaf-
fected. Despite the elevated GAL4-VP16 levels, overexpres-
sion of SUG-1WT or SUG-1m reduces the transcriptional
activation to V70% of the activator control alone (Fig. 3B,
lane 4 vs. 5, 6). The results indicate that ectopically overex-
pressed SUG-1WT and SUG-1m are acting as competitors for
an endogenous SUG-1 containing complex, which is involved
in both GAL4-VP16 degradation and GAL4-VP16-mediated
transcriptional activation.
To examine the role of Ub in GAL4-VP16-mediated tran-
scriptional activation, an Ub containing activator, Ub(G75A,
G76A)-VP16, was included in the experiments for transient
and reporter assay. Single Ub was directly fused to the N-ter-
minus of GAL4-VP16 activators to generate the correspond-
ing expression constructs. C-terminal glycine residues (glycine
75 and 76) of the Ub moiety in the activator were converted
to alanine residues to slow down the removal of Ub by iso-
peptidases. Such double mutation e¡ectively prevents Ub
from being cleaved. The Ub(G75A,G76A)-VP16 activator ap-
pears larger in size than parental GAL4-VP16 molecules and
the steady-state level of the activator remains comparable to
that of parent molecules (data not shown). Surprisingly, the
Ub(G75A,G76A)-VP16 activator had lower transcriptional
activation potency compared to that of parental GAL4-
VP16 molecules (Fig. 3B, lane 4 vs. 7). Seemingly, non-remov-
able Ub exerts a negative structural e¡ect on GAL4-VP16
molecules. Nevertheless, overexpressed SUG-1 and SUG-1m
had an enhanced inhibitory e¡ect on the transcriptional ac-
tivation by Ub(G75A,G76A)-VP16 activators. Overexpres-
sion of SUG-1 and SUG-1m causedV30% and 60% decrease
in the transcriptional activation by VP16 and Ub(G75A,
G76A)-VP16 (Fig. 3B, lanes 4^6 and 7^9), respectively. The
results strongly indicate that the Ub moiety plays a role in
recruiting a SUG-1 containing complex for transcriptional
activation.
3.4. Ub and Ubl domains of hHR23A retain proteasome-bound
general transcription factor (TFIIH)
To demonstrate the physical association of the proteasome
with general transcription factors, we applied a unique GST
pull-down assay using GST fusion proteins containing either
the Ub or the Ubl domain of hHR23A. The Ubl domain has
been reported to be a speci¢c ligand for the proteasome
through its interaction with the S5a (Rpn10 in yeast) subunit
of the 19S proteasome complex [26]. Ub, on the other hand,
binds the S2 (Rpn1 in yeast) subunit of the 19S proteasome
Fig. 4. Physical interactions between proteasome and general tran-
scription factor TFIIH. A: Both Ub and Ubl of hHR23A retain the
proteasome and general transcription factor TFIIH. WCE made
from HeLa cells were incubated with GST or GST-Ub or GST-Ubl
fusion proteins bound to glutathione Sepharose beads. After a thor-
ough washing, the retained proteins were resolved by sodium dodec-
yl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) and im-
munoblotted with antibodies against 19S proteasome components,
S1 and SUG-1 as well as antibody against TFIIH component, XPB.
B: Direct association between 19S proteasome and TFIIH. WCE
were subjected to GST-Ubl a⁄nity chromatography for Ubl binding
proteins. The bound proteins were eluted together with GST-Ubl
and co-immunoprecipitated with either normal rabbit IgG or anti-
XPB antibody. Immunoprecipitates were detected for the 19S pro-
teasome components S1 and SUG-1. C: SUG-1 interacts with XPB
in vitro. HeLa WCE were incubated with GST or GST-SUG-1 fu-
sion proteins bound to glutathione beads. The bound proteins were
resolved by SDS^PAGE and immunoblotted with antibody against
XPB.
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complex [27,28]. As expected, both GST-Ub and -Ubl pro-
teins retained S1 as well as SUG-1 subunits of 19S protea-
some complex, whereas neither of these two subunits was
detected with the GST protein alone (Fig. 4A). Notably,
XPB, a subunit of TFIIH, was also detected in both GST-
Ub- and -Ubl-bound proteins. Since Ubl of Rad23 does not
bind transcription factors directly [29], these results suggest
that the proteasome is associated with TFIIH in vivo. To
ensure that TFIIH binding was through interaction with the
proteasome and not a result of direct binding to Ubl, WCE
from HeLa cells were ¢rst subjected to GST-Ubl a⁄nity chro-
matography and then the GST-Ubl-bound fractions were used
for immunoprecipitation by an anti-XPB antibody. As shown
in Fig. 4B, both S1 and SUG-1 were found to co-immuno-
precipitate with TFIIH/XPB proteins. In addition, the pull-
down assay using GST-SUG-1 fusion protein further con-
¢rmed the interaction of SUG-1 with TFIIH (Fig. 4C). These
¢ndings are not only consistent with the previous observation
that SUG-1 interacts with TFIIH [30], but also indicate SUG-
1 as a subunit of proteasome in action. As the 20S proteasome
complex has not been found in the proteasome APIS (ATPase
independent of 20S)/transcription factor complex in yeast [29],
it appears that in mammalian cells, the 19S proteasome com-
plex, or at least its component subunit(s), is physically asso-
ciated with TFIIH in vivo.
4. Discussion
Many eukaryotic transcription factors are known to be de-
graded through the Ub-proteasome pathway. Increasing evi-
dence suggests that the degradation of transcription activators
can be associated with their transcriptional activation function
[5,31,32]. The possible association of degradation and tran-
scriptional activation processes has been further strengthened
by the observed convergence of transcription and proteolytic
signaling elements [3]. Such an association has been demon-
strated in estrogen-induced receptor K and retinoic acid-in-
duced receptor Q2 transactivation [33,34]. Here, we have dem-
onstrated that both proteasome and ubiquitylation function
are required for e⁄cient transcriptional activation mediated
by synthetic VP16 activators in mammalian cells. We have
also provided functional and biochemical data to suggest
that the 19S proteasome complex, or at least a fragment of
the 19S subunit, is recruited for the degradation as well as the
transcriptional activation by GAL4-VP16 in vivo. These re-
sults provide compelling evidence to support the linkage be-
tween the processes of proteolysis and accompanying trans-
activation.
The requirement of ubiquitylation for VP16 activator func-
tion has already been demonstrated in yeast [35]. We have
now extended this observation to mammalian cells and ex-
plored the function of the proteasome in transcriptional acti-
vation. Previous studies have shown that linking a single Ub
to activator speci¢cally causes transcriptional activation with-
out signaling protein degradation. Based on this ¢nding and
the observation that only the 19S regulatory subunit of the
proteasome is required for e⁄cient transcription elongation
[6], it is imaginable that both ubiquitylation and proteasome
have a non-proteolytic function in transactivation. However,
the observations provided in this and other studies [33,34]
clearly indicate that the proteasome is required for transcrip-
tional activation. Given the fact that impairment of protea-
some function by its inhibitor, MG132, leads to accumulation
of both native and Ub-conjugated substrates of the protea-
some, these observations suggest that the transcription process
is associated with proteolysis. Moreover, these observations
argue that proteolysis, a natural consequence of ubiquityla-
tion, must occur as transcription continues. This argument is
supported by an opposite case for yeast transcription factor
Met4. In that case, ubiquitylation of Met4 is directed by
SCF(Met30) Ub ligase, but both Met4 and its Ub conjugates
are relatively stable. While ubiquitylated Met4 associates with
target promoters, it fails to form a functional transcription
complex and negatively regulates Met4-mediated transcription
[36]. In essence, Ub plays a dual role in transcriptional acti-
vation and degradation.
The involvement of the 19S regulatory subunit of the pro-
teasome in transcription elongation provides a rationale for
the requirement of ubiquitylation in transcriptional activation.
As mentioned earlier, it has been demonstrated that the 19S
regulatory subunit is required for the e⁄cient transcription
elongation driven by the GAL4-VP16 activator in vitro and
that mutation in yeast SUG-1 inhibits the transcription elon-
gation in vivo [6]. Besides, it has recently been shown that a
19S proteasome complex is recruited to GAL1-10 promoter in
vivo [7]. These two lines of evidence suggest that attached Ub
may enhance the association between activator and 19S pro-
teasome proteins, although activator alone may be capable of
binding 19S proteins as seen for GAL4 AD. In this regard, we
have shown that the overexpressed proteasome component,
SUG-1, competitively reverses the degradation of GAL4-
VP16 but attenuates its transcriptional activation. Moreover,
overexpressed SUG-1 and SUG-1m had an enhanced inhibi-
tory e¡ect on transcriptional activation by Ub-attached acti-
vators. The inhibitory e¡ect of overexpressed SUG-1 and
SUG-1m could be explained due to its competition with en-
dogenous SUG-1 or impairment of normal proteasome func-
tion. Therefore, these data strongly suggest that Ub plays
an accessory role in associating the activator with 19S protea-
somal proteins. Moreover, the demonstrated association of
the Ub, proteasome and TFIIH further makes this a very
likely operating scenario. At the present juncture, the data
cannot help to discern the concrete involvement of either
the 19S proteasome complex or the individual 19S regulatory
subunits or even the complete 26S proteasome. Despite sev-
eral attempts, we were unable to detect an association of the
components of 20S proteasome with TFIIH through immuno-
precipitation with anti-XPB after GST-Ubl a⁄nity chroma-
tography (data not shown). It is possible that such associa-
tion, if any, is unstable. If degradation of the activator must
happen, then it is possible to envision that 26S proteasome
would also undergo a dynamic reconstruction. The degrada-
tion of the activator would allow rapid reprogramming of the
transcription or alternatively allow the transcription elonga-
tion to proceed [31,32,37]. When the proteolysis is complete, a
part of the 26S proteasome, perhaps the 19S regulatory sub-
unit or the base of 19S regulatory subunit, would be engaged
with the elongation step of transcription.
In conclusion, the regulation of viral VP16 TAD function,
by ubiquitylation and proteasomal protein degradation, re-
vealed in this study provides an important clue about how
transcription and factor degradation are tightly connected
processes in mammalian cells. A full understanding of the
mechanism and the role played by ubiquitin and proteasome
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in transcription will need in-depth studies of the events occur-
ring at an activated promoter and the cognate protein com-
plexes engaged in transcription. To address whether non-pro-
teolytic functions of ubiquitylation and proteasome are
involved in transcriptional activation, we are currently inves-
tigating whether LTrCP (a homolog of yeast Met30) is a com-
ponent of SCF E3 ligase for GAL4-VP16 and whether LTrCP
is recruited to the promoter region for its transactivation.
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